- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01781104
Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation
September 21, 2016 updated by: Motus Therapeutics, Inc.
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RM-131 Administered to Patients With Chronic Constipation
The purpose of this study is to evaluate safety and tolerability as well as the effects of RM-131 on colonic transit, bowel consistency, bowel habits, abdominal pain, and other abdominal symptoms in patients with chronic constipation.
Study Overview
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States
- Mayo Clinic Arizona
-
-
Florida
-
Jacksonville, Florida, United States
- Mayo Clinic Florida
-
-
Minnesota
-
Rochester, Minnesota, United States
- Mayo Clinic Rochester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria
- Able to provide written informed consent prior to any study procedures, and willing and able to comply with study procedures.
- Diagnosis of chronic IDIOPATHIC constipation, including experiencing constipation for 12 or more weeks in the preceding 12 months (defined by Rome III criteria for Functional Constipation, but all patients must meet the modified criterion of a history of ≤4 average defecations per week)
- Stable concomitant medications (no changes in regimen for at least 2 weeks prior to baseline period)
- Body mass index of 18-40 kg/m2
- Females must not be lactating or pregnant
Exclusion criteria
- Unable/unwilling to provide informed consent or to comply with study procedures
- Diagnosis of secondary constipation e.g. underlying general neurological disease such as Parkinsonism, multiple sclerosis, diseases associated with peripheral neuropathy, iatrogenic constipation
- Structural or metabolic diseases that affect the GI system NOTE: Patients with clinical suspicion of upper or lower GI obstruction must have been evaluated per standard of care and obstruction ruled out before screening
Unable to withdraw the following medications 48 hours prior to baseline period and throughout the study (except as protocol defined rescue medications):
- Medications that alter GI transit including laxatives, magnesium and aluminum containing antacids, prokinetics, erythromycin, narcotics, anti-cholinergics, tricyclic antidepressants, SNRI and newer antidepressants
- Selective serotonin reuptake inhibitor (SSRI) antidepressants are permissible at low, stable doses
- Analgesic drugs including opiates, NSAIDs and COX-2 inhibitors
- GABAnergic agents
- Benzodiazepines
- NOTE: stable doses of thyroid replacement, estrogen replacement, low dose aspirin for cardioprotection, and birth control (but with adequate backup contraception as drug-interactions with birth control have not been conducted) are permissible
- Drugs with a low therapeutic index, such as warfarin, digoxin, anti-seizure medications
- History of surgery within 60 days of screening
- Acute or chronic illness or history of illness, which in the opinion of Investigator, could pose threat/harm to the patient or obscure interpretation of laboratory test results or interpretation of study data such as frequent angina, Class III or IV congestive heart failure, moderate impairment of renal or hepatic function, poorly controlled diabetes, etc
- History of hypersensitivity to mannitol (an ingredient of both active and placebo study medications)
- Clinically significant abnormalities on screening laboratories or physical examination as determined by Investigator
- Abnormal 12-lead electrocardiogram (ECG), including evidence of acute myocardial or subendocardial ischemia and clinically significant arrhythmias or conduction abnormalities (including prolonged QTc > 500 msec) or abnormal blood pressure at screening except minor deviations deemed to be of no clinical significance by Investigator
- Acute GI illness within 48 hours of initiation of the baseline period
- ALT or AST > 1.2 X upper limit of normal during screening
- Females who are pregnant or breastfeeding
- History of excessive alcohol use or substance abuse
- Participation in an investigational clinical study within 30 days prior to dosing in the present study
- Any other reason, which in the opinion of the Investigator, would confound proper interpretation of the study
Exclusion criteria at the end of the baseline period
- In addition, patients will not be randomized into the double-blind treatment comparison if during the baseline period they:
- used rescue medications such as laxatives, beyond those allowed by protocol
- demonstrated lack of compliance
- averaged more than 4 spontaneous bowel movements per week
- Substudy patients only: did not demonstrate slow colonic transit at end of baseline period (GC 24 >2.4)
- Women of child-bearing potential: positive pregnancy test
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo delivered subcutaneously once daily for 14 days.
|
Active Comparator: RM-131
|
Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of RM-131 on colonic transit
Time Frame: End of 14 day Baseline and end of 14 day Treatment periods
|
Change from baseline colonic geometric center at 24 hours
|
End of 14 day Baseline and end of 14 day Treatment periods
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of RM-131
Time Frame: Duration of the study, an expected average of 9 weeks
|
Assessment of adverse events and clinical laboratory evaluations
|
Duration of the study, an expected average of 9 weeks
|
Effect of RM-131 on stool consistency
Time Frame: Daily for the duration of the study, an expected average of 9 weeks
|
Change in responses on Bowel Habit Diary Cards
|
Daily for the duration of the study, an expected average of 9 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Acosta A, Camilleri M, Busciglio I, Boldingh A, Nelson AD, Burton D. Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial. Dig Dis Sci. 2016 Mar;61(3):852-60. doi: 10.1007/s10620-015-3876-5. Epub 2015 Oct 14.
- Acosta A, Camilleri M, Kolar G, Iturrino J, Szarka LA, Boldingh A, Burton D, Ryks M, Rhoten D, Zinsmeister AR, Spence SC, Gottesdiener K, Bouras EP, Vazquez-Roque MI. Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial. Clin Gastroenterol Hepatol. 2015 Dec;13(13):2312-9.e1. doi: 10.1016/j.cgh.2015.04.184. Epub 2015 May 19.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2013
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
January 28, 2013
First Submitted That Met QC Criteria
January 29, 2013
First Posted (Estimate)
January 31, 2013
Study Record Updates
Last Update Posted (Estimate)
September 23, 2016
Last Update Submitted That Met QC Criteria
September 21, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RM-131-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
ProgenaBiomeRecruitingConstipation | Constipation - Functional | Constipation Chronic Idiopathic | Constipation (Excl Faecal Impaction)United States
-
Pamukkale UniversityRecruiting
-
Shanghai University of Traditional Chinese MedicineLonghua Hospital; Shanghai Municipal Hospital of Traditional Chinese MedicineRecruiting
-
Universidade Nova de LisboaCINTESIS - Center for Health Technology and Services ResearchRecruiting
Clinical Trials on RM-131
-
Motus Therapeutics, Inc.CompletedDiabetes Mellitus | Gastroparesis | Diabetes Mellitus ComplicationsUnited States
-
Motus Therapeutics, Inc.CompletedAnorexia NervosaUnited States
-
Motus Therapeutics, Inc.CompletedGastroparesis | Gastrointestinal Motility Disorder | Diabetes Mellitus Complications | Diabetes Mellitus Type 1 and 2United States
-
Motus Therapeutics, Inc.Mayo ClinicCompletedGastric MotilityUnited States
-
AllerganCompletedDiabetes Mellitus | Gastroparesis | Diabetes Mellitus ComplicationsUnited States, United Kingdom, Belgium, Israel, Germany, Poland, Sweden
-
Motus Therapeutics, Inc.Michael J. Fox Foundation for Parkinson's ResearchTerminatedParkinson's DiseaseUnited States
-
Motus Therapeutics, Inc.Mayo ClinicCompletedChronic ConstipationUnited States
-
Assiut UniversityCompletedIntraoperative ComplicationsEgypt
-
Purdue UniversityCompletedCardiovascular Risk Factor | Healthy DietUnited States
-
Rhythm Pharmaceuticals, Inc.Recruiting